Discovery of A New Prognostic Molecular Marker <italic style="font-style: italic">NKX2-3</italic> for Acute Myeloid Leukemia

WANG Wandi; CHANG Tao; JIANG Siyuan; HOU Qi; JIN Zhenyi; WU Xiuli

doi:10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).20240004.014

您当前的位置：

首页 >

文章列表页 >

Discovery of A New Prognostic Molecular Marker NKX2-3 for Acute Myeloid Leukemia

Preclinic Research | 更新时间：2024-02-22

- Discovery of A New Prognostic Molecular Marker NKX2-3 for Acute Myeloid Leukemia
- Journal of Sun Yat-sen University(Medical Sciences) Vol. 45, Issue 1, Pages: 63-68(2024)
- 作者机构：
  
  1.暨南大学基础医学与公共卫生学院血液学研究所，广东广州 510632
  2.暨南大学基础医学与公共卫生学院生物化学与分子生物学系广东广州 510632
  3.暨南大学基础医学与公共卫生学院病理学系广东广州 510632
- 作者简介：
  
  JIN Zhenyi， E-mail：jinzhenyi11@jnu.edu.cn
  WU Xiuli， E-mail： tjnwuxiuli@jnu.edu.cn
- 基金信息：
- DOI：10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).20240004.014
  CLC： R3
- Published：20 January 2024，
  
  Received：31 July 2023，
  
  Accepted：27 November 2023
扫描看全文
王婉頔,常桃,江思远等.急性髓系白血病新型预后分子标志物NKX2-3的发现[J].中山大学学报（医学科学版）,2024,45(01):63-68.

WANG Wandi,CHANG Tao,JIANG Siyuan,et al.Discovery of A New Prognostic Molecular Marker NKX2-3 for Acute Myeloid Leukemia[J].Journal of Sun Yat-sen University(Medical Sciences),2024,45(01):63-68.
王婉頔,常桃,江思远等.急性髓系白血病新型预后分子标志物NKX2-3的发现[J].中山大学学报（医学科学版）,2024,45(01):63-68. DOI： 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).20240004.014.

WANG Wandi,CHANG Tao,JIANG Siyuan,et al.Discovery of A New Prognostic Molecular Marker NKX2-3 for Acute Myeloid Leukemia[J].Journal of Sun Yat-sen University(Medical Sciences),2024,45(01):63-68. DOI： 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).20240004.014.

摘要

目的

通过分析生物信息数据库中影响急性髓系白血病（AML）患者的预后的分子标志物的表达，为进一步探索AML预后的新型分子标志物提供实验基础。

方法

从癌症基因组图谱（TCGA）生物信息数据库中的179例AML患者的预后数据进行差异性基因分析及生存分析；利用基因表达集锦（GEO）数据库中的GSE13159数据集的74例健康人（HI）骨髓标本与542例AML初发患者骨髓标本进行分析，检测差异性目的基因表达水平在AML初发患者与健康人中的差异性；收集初发18例AML患者的外周血及骨髓样本，同时收集年龄和性别匹配的20例健康志愿者的样本作为对照，采用实时荧光定量PCR验证差异基因在AML患者体内的表达水平。

结果

生物信息数据分析显示，根据R语言计算出的NK2转录因子相关基因位点3（

NKX2-3

）的最佳截断值0.051进行生存分析，发现与低表达

NKX2-3

的AML初发患者相比，高表达

NKX2-3

的AML初发患者总体生存率较差（

= 0.003 6）；与HI相比，

NKX2-3

在AML初发组患者中显著高表达（

0.001）；实时荧光定量PCR的验证结果也证实N

KX2-3-1

和

NKX2-3-2

在AML初发组患者中高表达，且与健康人组相比有显著相关性（

P =

0.000，

= 0.000）。

结论

NKX2-3

在AML初发组患者中高表达，且高表达

NKX2-3

的AML患者总体生存较差；

NKX2-3

可能与AML临床转归与预后密切相关。

Abstract

Objective

To analyze the expression of molecular marker affecting the prognosis of acute myeloid leukemia （AML） patients from bioinformatics database， thus providing an experimental basis for further exploration of a novel molecular marker for the prognosis of AML.

Methods

The prognostic data of 179 AML patients from The Cancer Genome Atlas （TCGA） database were examined for differential gene analysis and survival analysis. The bone marrow samples of 74 healthy individuals （HI） and 542 de novo AML patients in the dataset GSE13159 downloaded from the Gene Expression Omnibus （GEO） database were analyzed to detect the difference in the expression levels of differential target genes. Peripheral blood and bone marrow samples were collected from 18 de novo AML patients and 20 age- and gender-matched healthy controls， and real-time fluorescent quantitative PCR was used to validate the expression levels of the differential genes in the AML patients.

Results

Bioinformatics data analysis showed that the optimal cut-off value of Homo sapiens NK2 homeobox 3 （

NKX2-3

） calculated by R language was 0.051. Survival analysis revealed a statistically poorer overall survival in de novo AML patients with high

NKX2-3

expression than in those with low

NKX2-3

expression （

= 0.0036）.

NKX2-3

was highly expressed in patients with de novo AML than in HI and the difference was statistically significant （

0.001）. Real-time fluorescence quantitative PCR verified the expression levels of the

NKX2-3

gene in AML patients and confirmed that compared with those in HI， in the de novo AML patients，

NKX2-3-1

and

NKX2-3-2

were highly expressed and were significantly correlated （

= 0.000，

= 0.000）.

Conclusion

NKX2-3

is highly expressed in de novo AML patients， and the AML patients with high

NKX2-3

expression have poor overal survival.

NKX2-3

may be closely related to the clinical outcome and prognosis of AML.

关键词

急性髓系白血病NKX2-3生物信息学预后基因表达相关性

Keywords

acute myeloid leukemia （AML）NKX2-3bioinformaticsprognosisgene expressioncorrelation

references

Estey E， Döhner H. Acute myeloid leukaemia ［J］. Lancet， 2006， 368（9550）： 1894-1907.

Salerno L， Romeo G， Modica MN， et al. Heme oxygenase-1： a new druggable target in the management of chronic and acute myeloid leukemia ［J］. Eur J Med Chem， 2017， 142： 163-178.

雷胡芯，牛长春，杨程，等. 急性髓系白血病患者早期血清CCN1蛋白检测及临床价值［J］.重庆医科大学学报，2022，47（2）：197-200

Lei HX，Niu CC，Yang C，et al. Detection and clinical significance of serum CCN1 proteinin in patients with early acute myeloid leukemia［J］.J Chongqing Med Univ，2022，47（2）：197-200

Deschler B， Lübbert M. Acute myeloid leukemia： epidemiology and etiology ［J］. Cancer， 2006， 107（9）： 2099-2107.

Shallis RM， Wang R， Davidoff A， et al. Epidemiology of acute myeloid leukemia： recent progress and enduring challenges ［J］. Blood Rev， 2019， 36： 70-87.

Byrd JC， Mrózek K， Dodge RK， et al. Pretreatment cytogenetic abnormalities are predictive of induction success， cumulative incidence of relapse， and overall survival in adult patients with de novo acute myeloid leukemia： results from Cancer and Leukemia Group B （CALGB 8461）［J］. Blood， 2002， 100（13）： 4325-4336.

Slovak ML， Kopecky KJ， Cassileth PA， et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia： a Southwest Oncology Group/Eastern Cooperative Oncology Group Study ［J］. Blood， 2000， 96（13）： 4075-4083.

Grimwade D， Walker H， Harrison G， et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia （AML）： analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial ［J］. Blood， 2001， 98（5）： 1312-1320.

Abudourousuli A， Chen S， Hu Y， et al. NKX2-8/PTHrP Axis-Mediated Osteoclastogenesis and Bone Metastasis in Breast Cancer ［J］. Front Oncol， 2022， 12： 907000.

He Y， Liu XY， Gong R， et al. NK homeobox 2.2 functions as tumor suppressor in colorectal cancer due to DNA methylation ［J］. J Cancer， 2020， 11（16）： 4791-4800.

Li H， Wang J， Huang K， et al. Nkx2.5 Functions as a conditional tumor suppressor gene in colorectal cancer cells via acting as a transcriptional coactivator in p53-mediated p21 expression ［J］. Front Oncol， 2021， 11： 648045.

Heylen E， Verstraete P， Aerschot LV， et al. Transcription factor NKX2-1 drives serine and glycine synthesis addiction in cancer ［J］. Br J Cancer， 2023， 128（10）： 1862-1878.

Nagel S， Drexler HG. Deregulated NKL. Homeobox genes in B-cell lymphoma ［J］. Cancers （Basel）， 2019， 11（12）： 1874.

Robles EF， Mena-Varas M， Barrio L， et al. Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics ［J］. Nat Commun， 2016， 7： 11889.

Vojkovics D， Kellermayer Z， Kajtár B， et al. Nkx2-3-A slippery slope from development through inflammation toward hematopoietic malignancies ［J］. Biomark Insights， 2018， 13： 1177271918757480.

Deng M， Brägelmann J， Schultze JL， et al. Web-TCGA： an online platform for integrated analysis of molecular cancer data sets ［J］. BMC Bioinformatics， 2016， 17： 72.

Kwok CT， Marshall AD， Rasko JE， et al. Genetic alterations of m（6）A regulators predict poorer survival in acute myeloid leukemia ［J］. J Hematol Oncol， 2017， 10（1）： 39.

Mer AS， Lindberg J， Nilsson C， et al. Expression levels of long non-coding RNAs are prognostic for AML outcome ［J］. J Hematol Oncol， 2018， 11（1）： 52.

Wilop S， Chou WC， Jost E， et al. A three-gene expression-based risk score can refine the European LeukemiaNet AML classification ［J］. J Hematol Oncol， 2016， 9（1）： 78.

刘梦媛，郑翔，许永杰，等. 利用TCGA数据库研究ERGIC3在肺腺癌免疫微环境中的作用及其预后评价中的价值［J］.遵义医科大学学报，2022，45（4）：450-456.

Liu MY，Zheng X，Xu J，et al. Prognostic value of ERGIC3 and its role on immune microenvironment in lung adenocarcinoma based on TCGA database ［J］. J Zunyi Med Univ，2022，45（4）：450-456.

Jin Z， Lan T， Zhao Y， et al. Higher TIGIT（+） CD226（-） γδ T cells in patients with acute myeloid leukemia ［J］. Immunol Invest， 2022， 51（1）： 40-50.

Zheng J， Qiu D， Jiang X， et al. Increased PD-1（+） Foxp3（+） γδ T cells associate with poor overall survival for patients with acute myeloid leukemia ［J］. Front Oncol， 2022， 12： 1007565.

Jin Z， Ye W， Lan T， et al. Characteristic of TIGIT and DNAM-1 expression on Foxp3+ γδ T cells in AML patients ［J］. Biomed Res Int， 2020， 2020： 4612952.

Liao J， Coffman KA， LOCKER J， et al. Deletion of conserved non-coding sequences downstream from NKX2-1： A novel disease-causing mechanism for benign hereditary chorea ［J］. Mol Genet Genomic Med， 2021， 9（4）： e1647.

Teng F， Zhang J X， Chen Y， et al. LncRNA NKX2-1-AS1 promotes tumor progression and angiogenesis via upregulation of SERPINE1 expression and activation of the VEGFR-2 signaling pathway in gastric cancer ［J］. Mol Oncol， 2021， 15（4）： 1234-1255.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Significance of co-expression of RNA Binding Protein PTBP1 and p-AXL in Osteosarcoma

Clinical Significance of High Expression of Endoplasmic Reticulum Stress-related Proteins Glucose-regulating Protein 78 and X-box Binding Protein 1 induced by Fusobacterium Nucleatum in Esophageal Squamous Cell Carcinoma

RBMS3 Expression and Its Correlation with Clinicopathological Features and Prognosis of Epithelial Ovarian Cancer

Clinical Characteristics and Diagnostic Methods of Pulmonary Mucormycosis

Related Author

LI Xiang-xiang

XU Wen-li

LU Zheng-yu

HE An-fang

WANG Zhen

LIU Ni

LE Yu-ting

PENG Ting-sheng

Related Institution

Department of Pathology， The First Affiliated Hospital of Sun Yat-sen University

Department of Thoracic Surgery， Anyang Tumor Hospital // Henan Key Laboratory of Precision Medicine for Prevention and Treatment of Esophageal Cancer

College of Clinical Medicine of Henan University of Science and Technology // The First Affiliated Hospital of Henan University of Science and Technology // Henan Key Laboratory of Cancer Epigenetics // Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment

Department of Thoracic Surgery， The Third Affiliated Hospital of Xinxiang Medical University

Anhui Engineering Technology Research Center of Biochemical Pharmaceutical

Postal code：510080
Tel：020-87331643，87330827 Email：xbmed@mail.sysu.edu.cn
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Discovery of A New Prognostic Molecular Marker NKX2-3 for Acute Myeloid Leukemia

DOI：10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).20240004.014

摘要

Abstract

关键词

Keywords

references